Theme: Integrating prevention, laboratory research and clinical trials to combat Gynecologic cancer

Gynecologic Cancer 2016

Gynecologic Cancer 2016

Conferences Series LLC cordially invites all the participants across the globe to attend the “World Gynecologic Cancer conference” during October 17-18, 2016 at Rome, Italy.

Gynecologic cancers is an uncontrolled growth of abnormal cells that originate from the reproductive organs. There are several types of Gynecologic cancers which include cervicalovarianuterine/endometrial, vaginal and vulvar cancers.

Cervical cancer is a disease in which malignant (cancer) cells form in the tissues of the cervix. The cervix is the lower, narrow end of the uterus. The cervix leads from the uterus to the vagina (birth canal).Most cervical cancer is caused by a virus called human papillomavirus, or HPV. You can get HPV by having sexual contact with someone who has it. There are many types of the HPV virus. Not all types of HPV cause cervical cancer. Some of them cause genital warts, but other types may not cause any symptoms.

Ovarian cancer when cancer starts in the ovaries, it is called ovarian cancer. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you.

Endometrial cancer Or uterine cancer when cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman’s pelvis . The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of uterus, called the endometrium. When uterine cancer is found early, treatment works best.

Vaginal cancer when cancer starts in the vagina, it is called vaginal cancer. The vagina, also called the birth canal, is the hollow, tube-like channel between the bottom of the uterus and the outside of the body.

Vulvar cancer when cancer starts in the vulva, it is called vulvar cancer. The vulva is the outer part of the female genital organs. It has two folds of skin, called the labia. Vulvar cancer most often occurs on the inner edges of the labia.

Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is malignant (cancerous) if the cells can grow into (invade) surrounding tissues or spread to distant areas of the body. Breast cancer occurs almost entirely in women, but men can get it, too. Although many types of breast cancer can cause a lump in the breast, not all do. There are other symptoms of breast cancer you should watch out for and report to a health care provider.

Conference Series LLC is a pioneer and leading scientific event organizer, publishing around 700 Open access journals and conducting over 500 Scientific Meetings all over the globe annually with the support of more than 1000 scientific associations, 80,000 editorial board members, and 7.5 million followers to its credit.

Conference Series LLC  which is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe. Conference Series LLC organising a wide range of Cancer Conferences, Cancer meetings, Global Cancer Conferences, European Oncology Conferences, Surgical Oncology, like Skin cancer conferences, Breast Cancer Conferences, Liver Cancer Conferences, Gynecology Cancer Conferences, Lung Cancer meetings and Oncology Conferences where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions and which helps get possibilities for treating the diseases with new era, technology and research.

Why to attend???

With members from around the world focused on learning about Gynecologic Cancers; this is your best opportunity to reach the largest assemblage of participants from the Gynecologic Societies Cervical Cancer communityoncology societyEuropean oncology conferencesAmerican oncology society. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in World Gynecologic Cancer conference are the hallmarks of this conference.

For more details visit Gynecologic Oncology Meeting

Target Audience

·         Oncologists

·         Gynecologists

·         Radiologists

·         Pathologists

·         Scientists

·         Students

·         Researchers

·         Faculty

·         Gynecology Cancer Associations and Societies

·         Business Entrepreneurs

·         Training Institutes

·         Pharmaceutical Companies

·         Medical Devices Companies

·         Data Management Companies

 

 

Conference Series LLC invites all the participants across the globe to attend ‘World Gynecologic Cancer Conference’ October 17-18, 2016, at Rome, Italy which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Conference Series LLC, the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe.

With members from around the world focused on learning about Cancers; this is your best opportunity to reach the largest assemblage of participants from the The International Gynecologic Cancer Society  European Cervical Cancer Association,  International Papillomavirus Society , American Society for Colposcopy and Cervical PathologyThe British Gynaecological Cancer Society International Federation for Cervical Pathology and Colposcopy . Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in Gynecologic Cancers are hallmarks of this conference.

This Gynecologic Cancers conference will have two days of discussions on methods and strategies related to management, quality improvement of  Cancer as well as to explore the new ideas and concepts on global scale and the topics include Uterine CancerVaginal CancerOvarian CancerHPV related cancer. Gynecologic Cancers 2016 will mainly focus on the Cause of the cancer and its Symptoms, Prognosis, Types,  Stages, Tests, Clinical trials to screen for Gynecologic Cancers, Diagnosis and Treatment, Early detection and Prevention, Vaccine, Latest Research, Case Report.

Track 1: Gynecologic Cancers

Gynecologic cancer is an uncontrolled growth of abnormal cells that originate from the reproductive organs. There are several types of Gynecologic cancers which include cervicalovarianuterine/endometrial, vaginal, vulvar and Breast cancers. Each Gynecologic cancer is unique, with different signs and symptoms, different risk factors, and different prevention strategies. All women are at risk for Gynecologic cancers, and risk increases with age. When Gynecologic cancers are found early, treatment is most effective.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences |Oncology Conferences

 Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA;12th World Cancer Conference, September 26-28, 2016 London, UK; Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE

Track 2: Cervical Cancer

Cervical Cancer is one of the most common cancers in women worldwide. But in the United States and other countries where cervical cancer screening is routine, this cancer is not so common. Most cervical cancer is caused by a virus called Human papillomavirus, or HPV. There are many types of the HPV virus. Not all types of HPV cause cervical cancer. Some of them cause genital warts, but other types may not show any Cervical Cancer symptoms and signs. An infection may go away on its own. But sometimes it can cause genital warts or lead to cervical cancer. That's why it's important for women to have regular Pap tests. A Pap test can find changes in cervical cells before they turn into cancer cells. If you treat these cell changes, you may prevent cervical cancer.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ;  Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK

Track 3: Ovarian Cancer

Ovarian cancer when cancer starts in the ovaries, it is called ovarian cancer. Women have two ovaries that are located in the pelvis, one on each side of the uterus. The ovaries make female hormones and produce eggs.

Ovarian cancer causes more deaths than any other cancer of the female reproductive system. Ovarian cancer often causes signs and symptoms, so it is important to pay attention to your body and know what is normal for you.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Pancreatic Conference, September 26-27, 2016 Toronto, Ontario, Canada; 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE;14th World  Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA; Neuroendocrine Cancer Conference, Nov 7-9, 2016 Las Vegas, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29 – 31​, 2016 Lisbon, Portugal; Engineering and Physical Sciences in Oncology, June 25-28, 2016, Boston, Massachusetts; International Conference on Innovation and Biomarkers in Cancer Drug Development, September 8 - 9, 2016, Brussels, Belgium; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 – December 2, 2016, Munich, Germany; Molecular Biology in Clinical Oncology Workshop, July 24-31, 2016, Colorado, USA; ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, June 18-24, 2016, Zeist, The Netherlands;12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Colorectal Cancer Conference, September 26-27, 2016 Toronto, Ontario, Canada; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 4Endometrial Cancer

Endometrial  cancer or uterine cancer when cancer starts in the uterus, it is called uterine cancer. The uterus is the pear-shaped organ in a woman’s pelvis . The uterus, also called the womb, is where the baby grows when a woman is pregnant. The most common type of uterine cancer is also called endometrial cancer because it forms in the lining of uterus, called the endometrium. When uterine cancer is found early, treatment works best.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; 3th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016 Kuala Lumpur, Malaysia;  Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; 14th World  Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA; 48th Annual Congress of the International Society of Paediatric Oncology, October 19-22, 2016 Dublin, Ireland; ASCO Annual Meeting, June 3-7, 2016 Chicago, Illionois; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; 22nd Annual Meeting of the German Society for Radiooncology, June  16-19 Berlin, Germany; 8th Annual UAE Cancer Congress, October 22-23, 2016 Dubai, UAE; Breast Cancer Research Symposium, July 22-23, 2016 London, UK; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; World Cancer Congress , October 31 - November 3 Paris, France; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK,12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 5: Vaginal Cancer/Vulvar Cancer

Vaginal cancer when cancer starts in the vagina, it is called vaginal cancer. The vagina, also called the birth canal, is the hollow, tube-like channel between the bottom of the uterus and the outside of the body.

Vulvar cancer when cancer starts in the vulva, it is called vulvar cancer. The vulva is the outer part of the female genital organs. It has two folds of skin, called the labia. Vulvar cancer most often occurs on the inner edges of the labia.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Cancer Diagnostics Conference  June 13-15, 2016 Rome, Italy; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, Pennsylvania, USA; 12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016 Kuala Lumpur, Malaysia;16th Global Annual Oncologists Meeting, April 19-21, 2017 Zurich, Switzerland; ESMO Academy 2016, 26 Aug - 28 Aug 2016, Oxford, United Kingdom; ESMO Symposium on Immuno-Oncology 2016, 04 Nov - 06 Nov 2016,  Lausanne, Switzerland; 8th European Multidisciplinary Meeting on Urological Cancers, 24 Nov - 27 Nov 2016, Milan, Italy; ESMO Asia 2016 Congress, 16 Dec - 19 Dec 2016, Singapore, 48th Annual Congress of the International Society of Paediatric Oncology, 19 Oct - 22 Oct 2016, Dublin, Ireland; World Cancer Congress 2016, 31 Oct - 03 Nov 2016, Paris, France; The Annual Meeting: Future of Patient-Centered Care and Research, June 3-7, 2016, McCormick Place, Chicago; 2016 Annual Scientific Meeting,(COSA 2016) 15 - 17 November 2016, Queensland, Australia; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 6: Breast Cancer

 Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is malignant (cancerous) if the cells can grow into (invade) surrounding tissues or spread to distant areas of the body. Breast cancer occurs almost entirely in women, but men can get it, too. Although many types of breast cancer can cause a lump in the breast, not all do. There are other symptoms of breast cancer you should watch out for and report to a health care provider.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences |Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ;  Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai

Track 7: Gynecologic Cancers: Signs and Symptoms

Women with early cervical cancers and pre-cancers usually have no symptoms. Symptoms often do not begin until a pre-cancer becomes a true invasive cancer and grows into nearby tissue. When this happens, the most common symptoms are: Abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Bleeding after douching, or after a pelvic exam is a common symptom of cervical cancer but not pre-cancer. An unusual discharge from the vagina − the discharge may contain some blood and may occur between your periods or after menopause; Pain during sex (vaginal intercourse).

Ovarian cancer may cause several signs and symptoms. The most common symptoms include

  Bloating

  Pelvic or abdominal pain

  Trouble eating or feeling full quickly

  Urinary symptoms such as urgency or frequency

These symptoms are also commonly caused by benign (non-cancerous) diseases and by cancers of other organs. If a woman has these symptoms more than 12 times a month, she should see her doctor, preferably a gynaecologist.

Others symptoms of ovarian cancer can include:

Fatigue, Upset stomach, Back pain, Pain during sex, Constipation, Menstrual changes, Abdominal swelling with weight loss

Endometrial cancer Signs and Symptoms

The symptoms may include vaginal bleeding, such as a change in their periods or bleeding between periods or after menopause. This symptom can also occur with some non-cancerous conditions, but it is important to have a test. If you have gone through menopause already, it’s especially important to report any vaginal bleeding, spotting, or abnormal discharge to your doctor.

Pain in the pelvis, feeling a mass, and losing weight without trying can also be symptoms of endometrial cancer.

Vaginal cancer Signs and Symptoms

The may include

 Abnormal vaginal bleeding (often after intercourse)

 Abnormal vaginal discharge

 A mass that can be felt

 Pain during intercourse

Having these symptoms does not always mean that you have cancer. In fact, these symptoms are more likely to be caused by something besides cancer, like an infection. The only way to know for sure what’s causing these problems is to see a health care professional.

Vulva cancer Signs and Symptoms

Women with vulvar cancer may experience the following symptoms or signs. Sometimes, women with vulvar cancer do not show any of these symptoms.

A lump or growth in or on the vulvar area

·         A patch of skin that is differently textured or colored than the rest of the vulvar area

·         Persistent itching, pain, soreness, or burning in the vulvar area

·         Painful urination

·         Bleeding or discharge that is not menstrual blood

An ulcer that persists for more than one month

Breast Cancer Signs and Symptoms

The first symptoms of breast cancer are usually an area of thickened tissue in the woman's breast, or a lump. The majority of lumps are not cancerous; however, women should get them checked by a health care professional.

The symptoms includes

  A lump in a breast

  A pain in the armpits or breast that does not seem to be related to the woman's menstrual period

  Pitting or redness of the skin of the breast; like the skin of an orange

  A rash around (or on) one of the nipples

  A swelling (lump) in one of the armpits

 An area of thickened tissue in a breast

 One of the nipples has a discharge; sometimes it may contain blood

  The nipple changes in appearance; it may become sunken or inverted

  The size or the shape of the breast changes

  The nipple-skin or breast-skin may have started to peel, scale or flake.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; 11th Vaccines Conference, September 12-14, 2016 Phoenix, Arizona, USA 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016, France; NCRI Cancer Conference, November  6-9, 2016, London, UK,12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK.

Track 8: Gynecologic Cancers: Pathophysiology

Human papillomavirus (HPV) infection must be present for cervical cancer to occur. HPV infection occurs in a high percentage of sexually active women. However, approximately 90% of HPV infections clear on their own within months to a few years and with no squeal, although cytology reports in the 2 years following infection may show a low-grade squamous intraepithelial lesion. On average, only 5% of HPV infections will result in the development of CIN grade 2 or 3 lesions within 3 years of infection. Only 20% of CIN 3 lesions progress to invasive cervical cancer within 5 years and only 40% of CIN 3 lesions progress to invasive cervical cancer with 30 years. Because only a small proportion of HPV infections progress to cancer, other factors must be involved in the process of carcinogenesis.

Ovarian Cancer A small portion of ovarian cancers occur in women with inherited gene mutations linked to an increased risk of ovarian cancer. These include mutations in the BRCA1 and BRCA2 genes, as well as the genes related to other family cancer syndromes linked to an increased risk of ovarian cancer, such as PTENSTK11MUTYH associated polyposis, and the many genes that can cause hereditary nonpolyposis colon cancer (MLH1MLH3MSH2MSH6TGFBR2PMS1, and PMS2).

The exact cause of endometrial cancer is unknown. Some experts suspect that high levels of estrogen might be responsible for this disease. Progesterone and estrogen are female sex hormones produced in the ovaries. When the balance of these two hormones changes, the endometrium can change. Research has shown that increased estrogen without corresponding increased progesterone can thicken the endometrium and potentially increase the likelihood of cancer.

Women with HIV or AIDS may have an increased risk of vaginal cancer, as well as other cancers in the genital or anal area. This may be because HIV and AIDS lower immunity so that the body is less able to overcome HPV infection. But most women who have vaginal cancer do not have HIV or AIDS.

Vulva cancer HPV is responsible for the cause of vulvar cancer. HPV can be passed from one person to another during skin-to-skin contact. One way HPV is spread is through sex, including vaginal and anal intercourse and even oral sex.

Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ;  Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai,

Track 9: Gynecologic Cancers: Types

There are four types of cervical cancer. Out of these four two are the main types of cervical cancer.

Squamous Cell Cervical Cancer - eight out of 10 (80%) cervical cancers are diagnosed as squamous cell. Squamous cell cancers are composed of the flat cells that cover the surface of the cervix and often begin where the ecto cervix joins the endo cervix.

Adenocarcinoma Cervical Cancer – more than one in 10 cervical cancers are diagnosed as adenocarcinoma (15 - 20%). The cancer develops in the glandular cells which line the cervical canal. This type of cancer can be more difficult to detect with cervical screening tests because it develops within the cervical canal. Adenosquamous cancers are tumors that contain both squamous and glandular cancer cells. Other rare types of cervical cancer can include clear cell, small cell undifferentiated, lymphomas and sarcomas.

Metastatic Cervical Cancer- This is the cancer that has spread to other parts of the body.

Mixed Cervical Cancer - Occasionally, cervical cancer has features of both squamous cell cervical cancer and adenocarcinoma cervical cancer.

Types of ovarian cancer

Type 1: Epithelial ovarian cancer This is the most common type of ovarian cancer and occurs in around nine out of every 10 cases. The cancer arises from the cells that line or cover the ovaries.

Type 2 : Primary peritoneal cancer Primary peritoneal cancer is similar to epithelial ovarian cancer and is usually treated in the same way. However, it does not originate in the ovaries but in the lining of the peritoneum, which means even women who have had their ovaries removed can develop this type of ovarian cancer. Find out more about primary peritoneal cancer.

Type 3 : Germ cell tumours About five per cent of ovarian cancers are germ cell tumours - that is around one in 20 cases. The cancer arises in the cells that form eggs within the ovaries, and tend to be found in younger women. There are a number of different subtypes of germ cell tumour, which means each subtype is quite rare. Treatment should take place at a centre with expertise in dealing with this particular type of ovarian cancer. When treated by experts, they are normally curable.

Type 4 : Sex cord stromal cell tumours  Sex cord stromal cell tumours account for less than five per cent of ovarian cancer cases. They arise from the connective cells that hold the ovaries together and produce the female hormones.

Types of Endometrial cancer

Grades 1 and 2 endometrioid cancers are type 1 endometrial cancersType 1 cancers are usually not very aggressive and do not spread to other tissues quickly. Type 1 endometrial cancers are thought to be caused by excess estrogen. They sometimes develop from atypical hyperplasia, an abnormal overgrowth of cells in the endometrium .

A small number of endometrial cancers are type 2 endometrial cancer . Type 2 cancers are more likely to grow and spread outside the uterus, they have a poorer outlook .Type 2 cancers include all endometrial carcinomas that aren’t type 1, such as papillary serous carcinoma, clear-cell carcinoma, undifferentiated carcinoma, and grade 3 endometrioid carcinoma.

Uterine carcinosarcoma (CS) starts in the endometrium and has features of both endometrial carcinoma and sarcoma. In the past, CS was considered a type of uterine sarcoma, but doctors now believe that CS is a carcinoma that is abnormal and so no longer looks much like the cells it came from.

 

Types of Vaginal cancer

Squamous cell carcinoma About 70 of every 100 cases of vaginal cancer are squamous cell carcinomas. These cancers begin in the squamous cells that make up the epithelial lining of the vagina. These cancers are more common in the upper area of the vagina near the cervix. Squamous cell cancers of the vagina often develop slowly.

Adenocarcinoma Cancers that begin in gland cells are called adenocarcinomas. About 15 of every 100 cases of vaginal cancer are adenocarcinomas. The usual type of vaginal adenocarcinoma typically develops in women older than 50

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ;  Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-

Track 10: Gynecologic Cancers: Stages

There are four stages in cervical cancer.

Stage I: Stage I carcinoma is strictly confined to the cervix; extension to the uterine corpus should be disregarded. The diagnosis of both Stages IA1 and IA2 should be based on microscopic examination of removed tissue, preferably a cone, which must include the entire lesion.

Stage II: Stage II carcinoma that extends beyond the cervix, but does not extend into the pelvic wall. The carcinoma involves the vagina, but not as far as the lower third.

Stage III: Stage III carcinoma that has extended into the pelvic sidewall. On rectal examination, there is no cancer-free space between the tumor and the pelvic sidewall. The tumor involves the lower third of the vagina.

Stage IV: Stage IV carcinoma that has extended beyond the true pelvis or has clinically involved the mucosa of the bladder and/or rectum.

Stages of Ovarian Cancer

Stage I

The cancer is only within the ovary or fallopian tube. It has not spread to organs and tissues in the abdomen or pelvis, lymph nodes, or to distant sites.

Stage II

The cancer is in one or both ovaries or fallopian tubes and has spread to other organs (such as the uterus, fallopian tubes, bladder, the sigmoid colon, or the rectum) within the pelvis. It has not spread to lymph nodes or distant sites.

Stage III

The cancer is in one or both ovaries or fallopian tubes, and one or both of the following are present:

§  has spread beyond the pelvis to the lining of the abdomen

§  has spread to lymph nodes in the back of the abdomen

Stage IV

This is the most advanced stage of ovarian cancer. In this stage the cancer has spread to the inside of the spleen, liver, lungs, or other organs located outside the peritoneal cavity.

Stages of Endometrial Cancer

Stage I

T1, N0, M0: The cancer is only growing in the body of the uterus. It may also be growing into the glands of the cervix, but is not growing into the supporting connective tissue of the cervix. The cancer has not spread to lymph nodes or distant sites.

Stage II

T2, N0, M0: The cancer has spread from the body of the uterus and is growing into the supporting connective tissue of the cervix. The cancer has not spread outside of the uterus. The cancer has not spread to lymph nodes or distant sites.

Stage III

T3, N0, M0: Either the cancer has spread outside of the uterus or into nearby tissues in the pelvic area.

Stage IV

The cancer has spread to the inner surface of the urinary bladder or the rectum (lower part of the large intestine), to lymph nodes in the groin, and/or to distant organs, such as the bones, omentum or lungs.

Stages of Vaginal Cancer

Stage I (T1, N0, M0): The cancer has grown through the top layer of cells but it has not grown out of the vagina and into nearby structures (T1). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).

Stage II (T2, N0, M0): The cancer has spread to the connective tissues next to the vagina but has not spread to the wall of the pelvis or to other organs nearby (T2). (The pelvis is the internal cavity that contains the internal female reproductive organs, rectum, bladder, and parts of the large intestine.) It has not spread to nearby lymph nodes (N0) or to distant sites (M0).

Stage III: Either of the following:

T3, any N, M0: The cancer has spread to the wall of the pelvis (T3). It may (or may not) have spread to nearby lymph nodes (any N), but it has not spread to distant sites (M0).

 

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; 11th Vaccines Conference, September 12-14, 2016 Phoenix, Arizona, USA 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016, France; NCRI Cancer Conference, November  6-9, 2016, London, UK,12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK.

Track 11: Gynecologic Cancer: Treatment and Monitoring

Surgery

Surgery is the removal of the tumor and surrounding tissue during an operation. A surgical oncologist is a doctor who specializes in treating cancer using surgery. A hysterectomy is the removal of the uterus and cervix. Hysterectomy can be either a simple hysterectomy, which is the removal of the uterus and cervix, or a radical hysterectomy which is the removal of the uterus, cervix, upper vagina, and the tissue around the cervix.

Radiation therapy

Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A doctor who specializes in giving radiation therapy to treat cancer is called a Radiation Oncologist. Radiation therapy may be given alone, before surgery, or instead of surgery to shrink the tumor. Many women may be treated with a combination of radiation therapy and chemotherapy.

Chemotherapy

Chemotherapy is the use of drugs to destroy cancer cells, usually by stopping the cancer cells ability to grow and divide. Chemotherapy is given by a medical oncologist, a doctor who specializes in treating cancer with medication. Systemic chemotherapy is delivered through the bloodstream to reach cancer cells throughout the body. Common ways to give chemotherapy include an intravenous (IV) tube placed into a vein using a needle or in a pill or capsule that is swallowed (orally).

Immunotherapy

Another avenue of immunotherapy for Gynecologic and cervical cancers is adoptive T cell transfer. In this approach, T cells are removed from a patient, genetically modified or treated with chemicals to enhance their activity, and then re-introduced into the patient with the goal of improving the T cell immune system’s anti-cancer response.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Pancreatic Conference, September 26-27, 2016 Toronto, Ontario, Canada; 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE;14th World  Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA; Neuroendocrine Cancer Conference, Nov 7-9, 2016 Las Vegas, USA; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29 – 31​, 2016 Lisbon, Portugal; Engineering and Physical Sciences in Oncology, June 25-28, 2016, Boston, Massachusetts; International Conference on Innovation and Biomarkers in Cancer Drug Development, September 8 - 9, 2016, Brussels, Belgium; EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, November 29 – December 2, 2016, Munich, Germany; Molecular Biology in Clinical Oncology Workshop, July 24-31, 2016, Colorado, USA; ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research, June 18-24, 2016, Zeist, The Netherlands;12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Colorectal Cancer Conference, September 26-27, 2016 Toronto, Ontario, Canada; Women’s Health Conferences October 03-05, 2016 London

Track 12:Human papilloma Virus

HPV is consists of more than 150 related viruses. Some HPV types can causes cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males and females. But there are vaccines that can prevent infection with the most common types of HPV. HPV can transmit by having vaginal, anal, or oral sex with someone who has the virus. It is most commonly spread during vaginal or anal sex.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; 3th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016 Kuala Lumpur, Malaysia;  Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; 14th World  Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA; 48th Annual Congress of the International Society of Paediatric Oncology, October 19-22, 2016 Dublin, Ireland; ASCO Annual Meeting, June 3-7, 2016 Chicago, Illionois; 16th Biennial Meeting of the International Gynecologic Cancer Society, October 29-31​ Lisbon, Portugal; 22nd Annual Meeting of the German Society for Radiooncology, June  16-19 Berlin, Germany; 8th Annual UAE Cancer Congress, October 22-23, 2016 Dubai, UAE; Breast Cancer Research Symposium, July 22-23, 2016 London, UK; International Cancer Education Conference, September 14-16, 2016 Bethesda, USA; World Cancer Congress , October 31 - November 3 Paris, France; NCRI Cancer Conference, November 6-9, 2016 Liverpool, UK,12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 13: HPV Vaccines

There are three vaccines which are approved by the FDA to prevent HPV infection: Gardasil, Gardasil 9, and Cervarix. All three vaccines prevent infections with HPV types 16 and 18, two high-risk HPV that cause 70% of cervical cancers and an even higher percentage of some of the other HPV-associated cancer. Gardasil also prevents infection with HPV types 6 and 11, which cause 90% of genital warts.

How effective are HPV vaccines? HPV vaccines are highly effective in preventing infection with the HPV they target when given before initial exposure to the virus—which means before individuals begin to engage in sexual activity. In the trials that led to approval of Gardasil and Cervarix, these vaccines were found to provide nearly 100% protection against persistent cervical infections with HPV types 16 and 18 and the cervical cell changes that these persistent infections can cause.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

Cancer Diagnostics Conference  June 13-15, 2016 Rome, Italy; 2nd Prostate Cancer Conference, August 22-23, 2016 Philadelphia, Pennsylvania, USA; 12th World Cancer Conference, September 26-28, 2016 London, UK; 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016 Kuala Lumpur, Malaysia;16th Global Annual Oncologists Meeting, April 19-21, 2017 Zurich, Switzerland; ESMO Academy 2016, 26 Aug - 28 Aug 2016, Oxford, United Kingdom; ESMO Symposium on Immuno-Oncology 2016, 04 Nov - 06 Nov 2016,  Lausanne, Switzerland; 8th European Multidisciplinary Meeting on Urological Cancers, 24 Nov - 27 Nov 2016, Milan, Italy; ESMO Asia 2016 Congress, 16 Dec - 19 Dec 2016, Singapore, 48th Annual Congress of the International Society of Paediatric Oncology, 19 Oct - 22 Oct 2016, Dublin, Ireland; World Cancer Congress 2016, 31 Oct - 03 Nov 2016, Paris, France; The Annual Meeting: Future of Patient-Centered Care and Research, June 3-7, 2016, McCormick Place, Chicago; 2016 Annual Scientific Meeting,(COSA 2016) 15 - 17 November 2016, Queensland, Australia; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 14: Gynecologic Cancers: Surgical Methods

Surgery is most often used to treat very early cancers.

Debulking epithelial ovarian cancer

The other important goal of surgery is to remove as much of the tumor as possible − this is called debulking. Debulking is very important in any patient with ovarian cancer that has already spread widely throughout the abdomen at the time of surgery.

Sometimes the surgeon will need to remove a piece of colon to debulk the cancer properly. In some cases, a piece of colon is removed and then the 2 ends that remain are sewn back together. In other cases, though, the ends can’t be sewn back together right away. Instead, the top end of the colon is attached to an opening in the skin of the abdomen to allow body wastes to get out.

Cryosurgery

A metal probe cooled with liquid nitrogen is put in the vagina and on the cervix. This kills the abnormal cells by freezing them. Cryosurgery is used to treat stage 0 cancers (carcinoma in situ), but it is not used for invasive cancer.

Laser surgery

A laser beam is used to burn off cells or to remove a small piece of tissue for study. Laser surgery is used for stage 0 cancers (carcinoma in situ), but it is not used for invasive cancer.

Hysterectomy

In a hysterectomy, the uterus and cervix are removed. The ovaries and fallopian tubes or pelvic lymph nodes may be taken out during the same operation, but this isn't a part of every hysterectomy. Some very early stage-I cervical cancers are treated with a hysterectomy. A hysterectomy is also used for some stage 0 cancers if the cone biopsy didn’t remove all the cancer. In Radical hysterectomy the surgeon removes more than just the uterus.

Trachelectomy

A procedure called a radical trachelectomy lets certain young women with early stage cervical cancer is treated without losing their ability to have children. This method takes out the cervix and the upper part of the vagina but leaves the body of the uterus behind. The doctor puts in a "purse-string" stitch to act as an opening of the cervix inside the uterus.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

14th World Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA;  Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA;  Leukemia Conference, October 17-18, 2016, Rome, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Rome, Italy; Nuclear Medicine and Radiation Therapy Conference,  July 14-15, 2016 Cologne, Germany;  2nd International Cancer Study & Therapy Conference,  Feb 20-22, 2017 Baltimore, USA;  The annual ESMO congress, Copenhagen, Denmark - 07 Oct - 11 Oct 2016;  Molecular Analysis for Personalised Therapy Conference,  London, United Kingdom - 23 Sep - 24 Sep 2016; Multidisciplinary Management of Lung Cancer, June 26-28, 2016, Russia; Multidisciplinary Management of Head and Neck Oncology, June 26-29, 2016, Italy, 12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE, Breast Cancer Conferences October 03-05, 2016 London, UK;  Bone Marrow Transplantation Conference, October 17-18, 2016, Rome, Italy; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 15: Gynecologic Cancers: Early Detection and Prevention

The best way to find Gynecologic cancers early is to have regular screening with a Pap test (which may be combined with a test for human papilloma virus or HPV). As Pap testing became routine in this country during the past half century, finding pre-invasive lesions (pre-cancers) of the cervix became far more common than finding invasive cancer. Being alert to any signs and symptoms of  Gynecologic cancers   can also help avoid unnecessary delays in diagnosis. Early detection greatly improves the chances of successful treatment and prevents any early cervical cell changes from becoming cancerous cell. Screening tests offer the best chance to have Gynecologic cancers found at an early stage when successful treatment is likely. If it’s detected early, it can be treated easily.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

11th Vaccines Conference, September 12-14, 2016 Phoenix, Arizona, USA 13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai, UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016, France; NCRI Cancer Conference, November  6-9, 2016, London, UK,12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE, Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK, Women’s Health Conferences October 03-05, 2016 London, UK.

Track 16:  Gynecologic Cancers: Screening and Diagnosis

The following procedures may be used:

Physical Exam and History: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient health habits and past illnesses and treatments will also be taken.

Pap Test: A procedure to collect cells from the surface of the cervix and vagina. A piece of cotton, a brush, or a small wooden stick is used to gently scrape cells from the cervix and vagina. The cells are viewed under a microscope to find out if they are abnormal. Pap test  procedure is also called a pap smear.

Human Papillomavirus (HPV) Test: A laboratory test used to check DNA or RNA for certain types of HPV  infection. Cells are collected from the cervix and DNA or RNA from the cells is checked to find out if an infection is caused by a type of HPV that is linked to vaginal cancer.

Biopsy: If abnormal cells are found in a Pap test, the doctor may do a biopsy. A sample of tissue is cut from the cervix and viewed under a microscope by a pathologist to check for signs of cancer. A biopsy that removes only a small amount of tissue is usually done in the doctor’s office

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

7th Cancer Biomarkers Conference, September 15-16, 2016 Berlin, Germany; 12th World Cancer Conference, September 26-28, 2016 London, UK; 8th  Biomarkers Conference, December 05-07, 2016 Philadelphia, USA;  8th Clinical Research Conference, December 05-07, 2016 Philadelphia, USA; 12th Annual Biomarkers & Diagnostics World Congress, May 16-19 Philadelphia, USA; 43rd International Society of Oncology and Biomarkers, September 1-6, 2016 Chicago, USA; International Summit on Biomarkers and Therapeutic Advances in Radiation Oncology, June 20-22, 2016 Montreal, Canada; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17,2016 Paris, France; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA,12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; 7th Molecular Conference, September 15-16, 2016 Berlin, Germany; ConferenceWorldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; 8th Clinical Research Conference, December 05-07, 2016 Philadelphia, USA; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 17:  Gynecologic Cancers: Vaccine

Three vaccines are available for the prevention of HPV-associated dysplasia and neoplasia, including cervical, vulvar, vaginal, and anal cancer; genital warts (condylomata acuminata); and precancerous genital lesions. The vaccines include Human papillomavirus vaccine- nonavalent (Gardasil 9), Human papillomavirus vaccine-quadrivalent (Gardasil), Human papillomavirus vaccine-bivalent (Cervarix). Advances in primary and secondary interventions for cervical cancer also include human papillomavirus prophylactic vaccines and testing. Recommended schedule for administering HPV vaccine, dosage of vaccine, vaccine series and minimum intervals of doses of vaccines should be monitored. Nonavalent HPV vaccine may prevent nearly 90% of Cervical and Gynecologic cancers.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

14th World Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA;  Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA;   Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  Nuclear Medicine and  Radiation Therapy Conference, July 14-15, 2016 Cologne, Germany;  2nd International Cancer Study & Therapy Conference,  Feb 20-22, 2017 Baltimore, USA;  The annual ESMO congress, Copenhagen, Denmark - 07 Oct - 11 Oct 2016;  Molecular Analysis for Personalised Therapy Conference,  London, United Kingdom ,23 Sep - 24 Sep 2016;  12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE;  Leukemia Conference, October 17-18, 2016, Rome, Italy; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 18:  Gynecology Oncology: Research

Improved detection and screening methods: Gynecologic cancers is highly treatable when detected early, researchers are developing better ways to detect pre cancer and Gynecologic cancers.

HPV Prevention: As discussed in the Prevention section, the HPV vaccines help prevent infection from the HPV strains that cause most Gynecologic cancers. Researchers are looking at the impact of the HPV vaccine to reduce the risk of HPV transmission.

Fertility-preserving surgery: There is continued interest in improving surgical techniques and finding out which patients with Gynecologic cancers can be treated successfully without the loss of fertility.

Targeted therapy: Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. Drugs called anti-angiogenesis inhibitors that block the action of a protein called vascular endothelial growth factor (VEGF) have been shown to increase the cancer’s response to treatment and survival in women with cervical cancer that has spread to other parts of the body. VEGF promotes angiogenesis, which is the formation of new blood vessels. Because a tumor needs the nutrients delivered by blood vessels to grow and spread, the goal of anti-angiogenesis therapies is to “starve” the tumors.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

2nd  Bio Pharmaceutics Conference, September 14-16, 2016 San Antonio, Texas, USA; 2nd Biologic Drugs Conference, September 14-16, 2016 San Antonio, Texas, USA; 3rd World  Pharmacology Congress, August 08-10, 2016 Birmingham, UK; 3rd 3D Models & Drug Screening Conference, 11- 12 May 2016, Berlin, Germany; Sixth European Workshop in Drug Synthesis 15- 19 May 2016, Siena, Italy 2nd Annual Formulation & Drug Delivery Congress 2016, 18-19 May 2016, London UK ; Vaccine Technology VI ,12-17 Jun 2016, Albufeira, Portugal London, United Kingdom; 12th Oncology Conferences Europe September 26-28, 2016 London, UK; 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 19: Oncology Nursing and Primary care

With the current challenges in the healthcare system, patients and professionals are uncertain about the role, responsibilities, and communication patterns of primary care professionals during cancer care. Oncology and primary care nurses should be surveyed to attain current and preferred roles in cancer care across the care continuum. Who coordinates the care, who makes the referrals, who manages the comorbidities? What is the optimal interface between oncology and primary care nurses in care delivery? How does the environment of care support or impede bidirectional communication among providers and with the patient? We need to test interventions to determine what model produces the best patient-centered outcomes, the best coordinated care. We need to document that coordinated care improves outcomes.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

7th Cancer Biomarkers Conference, September 15-16, 2016 Berlin, Germany; 12th World Cancer Conference, September 26-28, 2016 London, UK; 8th  Biomarkers Conference, December 05-07, 2016 Philadelphia, USA;  8th Clinical Research Conference, December 05-07, 2016 Philadelphia, USA; 12th Annual Biomarkers & Diagnostics World Congress, May 16-19 Philadelphia, USA; 43rd International Society of Oncology and Biomarkers, September 1-6, 2016 Chicago, USA; International Summit on Biomarkers and Therapeutic Advances in Radiation Oncology, June 20-22, 2016 Montreal, Canada; 6th Munich Biomarker Conference, November 29-30, 2016 Munchen, Germany; 18th International Conference on Biomarkers and Clinical Medicine, May 16-17,2016 Paris, France; 4th Annual Immuno-Oncology Summit, August 29-September 2, 2016 Boston, USA; 2nd Biomarkers, Diagnostics & Clinical Research Conference, September 19-20 Boston, USA; Biomarkers and Targeted Therapeutics in Sjögren’s (BATTS) Conference, September 19-22, 2016 Oklahoma, USA,12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; 7th Molecular Conference, September 15-16, 2016 Berlin, Germany; ConferenceWorldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; 8th Clinical Research Conference, December 05-07, 2016 Philadelphia, USA; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 20:Cancer Pharmacology

Cancer pharmacology plays a key role in drug development. In both the laboratory and the clinic, cancer pharmacology has had to adapt to the changing face of drug development by establishing experimental models and target orientated approaches. Based upon a greater understanding of the molecular aspects of cancer, new opportunities for therapeutic intervention have emerged that are effectively 'target orientated'.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences |Oncology Conferences

14th World Cancer Therapy Congress, December 05-07, 2016 Philadelphia, Pennsylvania, USA;  Radiation Oncology Conference, November 21-22, 2016 Dubai, UAE; Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA;   Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  Nuclear Medicine and  Radiation Therapy Conference, July 14-15, 2016 Cologne, Germany;  2nd International Cancer Study & Therapy Conference,  Feb 20-22, 2017 Baltimore, USA;  The annual ESMO congress, Copenhagen, Denmark - 07 Oct - 11 Oct 2016;  Molecular Analysis for Personalised Therapy Conference,  London, United Kingdom ,23 Sep - 24 Sep 2016;  12th Oncology Conferences Europe September 26-28, 2016 London, UK, 12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016 Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE;  Leukemia Conference, October 17-18, 2016, Rome, Italy; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE; Breast Cancer Conferences October 03-05, 2016 London, UK; Women’s Health Conferences October 03-05, 2016 London, UK.

Track 21:  Gynecologic Cancers: Case Report

Gynecologic Cancers  case reports play a crucial role in moving new treatments to patients who need those most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practice. Oncology Aesthetics is the practice of safe and beneficial spa services by individuals trained to understand how cervical cancer and associated medical treatments affect the body. Gynecologic Oncology nutrition includes the current therapies used to treat the cancer and nutrition related side effects. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients.

Related Gynecology Cancer Conferences| Cervical Cancer Conferences Oncology Conferences

12th World Cancer Conference, September 26-28, 2016 London, UK;  Surgical Oncology Conference, October 03-05, 2016 Atlanta, Georgia, USA; ;  Leukemia Conference October 17-18, 2016, Italy;13th Asia-Pacific Oncologists Annual Meeting, October 17-19, 2016, Malaysia; 14th World Cancer Convention, November 21-23, 2016 Dubai ,UAE; 18th International Psycho Oncology Society Congress, October 17-21, 2016, Ireland; ESMO World Congress on Gastrointestinal Cancer 2016, June 29-July 2, 2016, Spain; ESMO Symposium on Immuno-Oncology 2016, November 4-6, 2016, Switzerland; ESMO Asia 2016 Congress, December 16-19, 2016, Singapore;  ;  Leukemia Conference October 17-18, 2016, Italy; Bone Marrow Transplantation Conference, October 17-18, 2016, Italy;  European Lung Cancer Conference, May 5-8, 2017, Switzerland; ESMO 2017 Congress, September 8-12, 2017, Spain; World Cancer Congress, October 31-November  3, 2016,France; NCRI Cancer Conference, November  6-9, 2016, London, UK;12th Oncology Conferences Europe September 26-28, 2016 London, UK;12th Cancer Science Events Europe September 26-28, 2016 London, UK; Cancer Global Conferences Middle East November 21-23, 2016,Dubai, UAE; Oncology Conferences November 21-23, 2016 Dubai, UAE; Worldwide Cancer Events November 21-23, 2016 Dubai, UAE;  Women’s Health Conferences October 03-05, 2016 London, UK

 

 

 

 

 

 

 

 

 

 

Summary

Gynecologic Cancer is the field of medicine that focuses on cancers of the female generative system. As experts they have wide training in the diagnosis and treatment of this cancer.In 2012, there were about 4.7 million cases of women cancer worldwide in which 54% cases arose in less developed countries. Although the occurrence and mortality from Gynecologic cancer are major, other cancers are very uncommon. Primary cancers of the vulva, vagina, placenta and adnexa total 0.6% of all woman cancers.

Gynecologic Cancers Statistics

In the world 82,000 women are identified with Gynecologic Cancer each year. In 2013, an expected 91,730 were diagnosed. An estimated 88,000 new cases of Gynecologic Cancer were expected to be diagnosed in 2014 in the Europe, and over 29,000 females will lose their battle with this deadly disease. In addition to imposing a significant load on patients and their relations, Gynecologic Cancer places a major burden on the health care organization. Cancer-related diseases and death for advanced and recurrent Gynecologic Cancer malignancies remain at intolerable stages.Every woman is at risk for emerging a Gynecologic Cancer. It is expected that there will be about 98,000 new cases diagnosed and around 30,000 deaths from Gynecologic Cancer in the Italy during 2015.

Scope and Importance of Gynecologic Cancer Research

Gynecologic Cancer is the third most commonly diagnosed cancer and the leading cause of cancer death in females’ worldwide, accounting for 9% (529,800) of the total new cancer cases and 8% (275,100) of the total cancer deaths among females. More than 85% of these cases and deaths occur in developing countries.

Early detection of tumour biology and treatment of Gynecologic Cancer in younger women is more as compared to older women. Effort was devoted to the type of problems met in conducting the analyses and, where data were inadequate, recommending research guidelines or approaches.

Physicians are also involved in leading-edge programs in the prevention of cervical and Gynecologic Cancer through regular screenings and the identification of precancerous cervical lesions associated with papilloma virus infections.

Organized screening procedures can support to detect Gynecologic Cancer

A pap smear can identify Gynecologic Cancer. It is suggested to begin analysis every three years early at age 21.

1.     A pelvic exam images the rectum, vagina, cervix, fallopian tubes, uterus, ovaries, and Pelvic tests should be done annually, beginning at 21 and can help detect irregularities of the female reproductive system.

2.     An endometrial tissue sample checks for abnormal cells or signs of uterine cancer which can be done for women with a high risk for endometrial cancer due to an inborn susceptibility or when there are symptoms that need to be evaluated.

Members Associated Gynecologic Cancer Research

Gynecologic Cancer research associated members in Rome are about 418, in Italy 5684 members and worldwide about 10214 research members.

Hospitals Associated with Gynecologic Cancer Research

Major Gynecologic Cancer associated hospitals in Rome are around 3% when compared to worldwide.

Hospitals in Europe are:

St James Institute of Oncology

Velindre Cancer Centre

St Mary's Hospital  

Glenfield Hospital

Cancer Research UK Manchester Institute

Glan Clwyd Hospital 

University of London - The Institute of Cancer

Trafford General Hospital

Wythenshawe Hospital

Spire Manchester Hospital

The Christie

The Royal Marsden Hospital

UCL Cancer Institute

Weston Park Hospital

The Clatter Bridge Cancer Centre

UCH Macmillan Cancer Centre

Edinburgh Cancer Research Centre

Mount Vernon Cancer Centre

Elstree Cancer Centre

Parkside Hospital and Cancer Centre London

HCA Hospitals

The Royal Marsden

Queen Elizabeth Hospital

Papworth Clinic

Societies Associated with Gynecologic Cancer Research

In world there are about 9,685 societies which are specifically associated with Gynecologic Cancer, in which 1289 societies are from Europe and the remaining 269 societies are from Rome.

Association of European Cancer Leagues ECL

The European Consortium for Cervical Cancer Education

National Cancer Institute

Macmillan Cancer Support

Europe European Association for Neuro Oncology EANO

Europe European Breast Cancer Coalition EUROPA DONNA

Europe European Cancer Organization ECCO

Europe European Group for Blood and Marrow Transplantation EBMT

Europe European Musculo-Skeletal Oncology Society EMOS

Europe European Network of Cancer Registries

Europe European Neurofibromatosis Association

Europe European Oncology Nursing Society EONS

Europe European Organization for Research and Treatment of Cancer.

Europe European Organization for Research and Treatment of Cancer-Gynecological Cancer Group

EORTC Gynecologic Oncology

Europe European Organization for Treatment of Trophoblastic Disease

Europe European Prostate Cancer Coalition

Europe European Registry of Hereditary Pancreatitis and Familial

Europe European Research Organization on Genital Infection and

Europe European School of Oncology ESO

Europe European Society for Medical Oncology ESMO

Europe European Society for Therapeutic Radiation and Oncology

Industries Associated with Gynecologic Cancers Research

Industries associated with Gynecologic Cancer over all the world is about 80% in which 14% of industries are in Italy and in Rome about 6%.

·        Johnson & Johnson

·        Novartis

·        Roche

·        Pfizer

·        Sanofi

·        Merck

·        Bristol-myers squibb

·        Eli Lilly

·        Celgene

·        Takeda

·        AstraZeneca

·        Bayer

·        Amgen Celgene

·        Otsuka

·        Pharmacyclics

·        Incyte

Universities Associated with Gynecologic Cancer Research

Arcispedale S. Maria Nuova Hospital, Reggio Emilia, Italy

University Hospital San Martino- IST - National Institute for Cancer Research, Genoa, Italy

Oncological Referral Center - National Cancer Institute, Aviano Italy

Oncological Referral Center of Basilicata Rionero in Vulture, Italy

European Institute of Oncology Milan Italy

San Raffaele Hospital in Milan Italy

Institute of Molecular Oncology Milan Italy

Institute for Pharmacological Research Mario Negri, Milan Italy

National Institute for the Study and Treatment of Cancer Foundation  G.Pascale ' Milan Italy

Oncology Institute Veneto Italy

Institute Regina Elena / Regina Elena Cancer Institute, Rome Italy

Romagnolo Scientific Institute for Treatment of Cancer Italy

Institute of Oncology, Italy

The International Neuroscience Institute Hannover, Gerniar

Gustave Roussy Institute Villejuif Paris

Market Value on Gynecologic Cancer Research

The global Gynecologic Cancer market in 2010 was valued at $54bn, an increase of 5.1% over the previous year‘s sales of $51.3bn, and is forecasted to grow at a CAGR of 6.9% from 2010–16, reaching $81bn in 2016.

·        Collectively, the seven major markets (US, 5EU, and Japan) represented 79.1% (or $43bn) of in the global cancer market in 2010. In terms of size, the US dominated the global cancer market, with 2010 sales of $21bn and a market share of 38.5%.

·        The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. Collectively, the leading 10 brands accounted for almost 58.2% (or $31.4bn) of the global cancer market in 2010.

·        In 2010 antineoplastics was the leading drug class in the global cancer market. The global antineoplastic market was valued at $46bn in 2010 at a year-on-year (Y-o-Y) growth of 7.3%. The major drugs that contributed to the 2010 sales in the antineoplastic category were Roche‘s Avastin (bevacizumab) at $6.2bn, Herceptin (trastuzumab) at $5.2bn, and MabThera (rituximab) at $5.1bn, with Y-o-Y sales growth of 3.8%, 3.1%, and 3.3% respectively.

·        The cytostatic hormonal market registered 2010 sales of $8bn at a Y-o-Y decline of 6.5%. AstraZeneca‘s Arimidex (anastrozole) and Novartis‘s Femara (letrozole) led this class, reaching sales of $1.5bn and $1.3bn respectively in 2010

Market Growth of Gynecologic Cancer Research in the last and upcoming ten years

Tech Navio's analysts forecast the Global Gynecologic Cancer market to grow at a CAGR of 12.47% over the period 2013-2018. One of the key factors contributing to this market growth is the increase in prevalence of Gynecologic Cancer. The Global Gynecologic Cancer market has also been witnessing the emergence of personalized medicines. However, the increase in use of CAM could pose a challenge to the growth of this market. In next ten years as population ages, the number of people diagnosed with cancer is expected to be double. The volume of cancer services continues to grow. Radiation therapy by 3%,infusion therapy by 7%;Gynecologic services by 10%(annually).With earlier detection, cancer patients will be identified earlier with improvements in chemotherapy, patients will be able to tolerate more treatments, all of which will result in more treatments per patient and more lives saved.

Products manufactured by the industry related GynecologicCancer Research

Market Value:

·        Neosar (Cyclophosphamide)- manufactured by Roxane Laboratories Inc and the market value is

         17.06$

·        Paraplat (Carboplatin)-manufactured by Bristol-Myers Squibb Company and the market value is128$

·        Platinol (Cisplatin)-manufactured by Bristol-Myers Squibb Company and the market value is15.3$

·        Gemzar (Gemcitabine Hydrochloride)-manufactured by Eli Lilly and Company and the market value is             26.1$

·        Clafen (Cyclophosphamide)-manufactured by Selleckchem and the market value is150$

 

 

 

 

 

 

 

Gynecologic Oncology 2016

 

The success of the Gynecology & Obstetrics conference has given us the prospect to bring the gathering one more time. Conferenceseries LLC hosted the “Experts Meeting on Gynecologic Oncology” during May 19-21, 2016 at Hilton San Antonio Airport Hotel, San Antonio, USA,

The conference was focused on Gynecologic Cancers and Breast cancer Research studies with the theme “Integrating the Milestones in Gynecologic Oncology Globally”. The meeting engrossed a vicinity of comprehensive discussions on novel subjects like ovarian cancer, Breast cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer.

The conference was embarked with an opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

 

  • Dr. Sandra S. Hatch, The University of Texas Medical Branch, USA
  • Dr. Sherry Bradford, AccuTheranostics, Inc, USA
  • Dr. Hirendranath Banerjee, Elizabeth City State University, USA
  • Dr. Karl Reinhard Aigner, Medias Klinikum GmbH & Co KG, Germany
  • Mr. Adrian Senderowicz, CeruleanPharma, Inc., USA
  • Dr. Magdalena Klink, Polish Academy of Sciences, Poland

 

Best Poster Awardees:

Sean S. Jacob: University of Central Florida, USA

Alexis Barfield: USA

Dorothy Crumity: USA

Conferenceseries LLC offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Conferenceseries LLC and supported the conference in every aspect, without which the conference would not have been possible.


Past Reports  Gallery  

Cancer Science-2013

The 3rd World Congress on Cancer Science & Therapy was organized by OMICS Group Inc., during October 21-23, 2013 at Double Tree by Hilton Hotel San Francisco Airport, USA. The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 25 countries, who have driven this event into the path of success. The conference had multiple sessions, Keynote presentations, panel discussions and Poster sessions. Dr. Jimmy T. Efird, Brody School of Medicine, USA Was honorable Moderator for the conference. The conference proceedings were carried out through various Keynote-presentations by: Dr. Stewart Sell, Wadsworth Center, USA, Dr. Michael Retsky, Harvard School of Public Health, USA, Dr. Jimmy T. Efird, Brody School of Medicine, USA and the wonderful workshop session was organized by Dr. Dorothee Herlyn, The Wistar Institute, USA.


Past Reports  Gallery  

Cancer Science-2012

OMICS Group’s 2nd World Congress on Cancer Science & Therapy was held during September 10-12, 2012 at Hilton San Antonio Airport, San Antonio, USA.

The conference proceedings were carried out through effectual keynote lectures by:Dr. Sudhakar Akul Yakkanti, Boys Town National Research Hospital, USA,Dr. Alexei G. Basnakian, University of Arkansas for Medical Sciences, USA,Dr. Dan Dixon, University of South Carolina, USA,Dr. Sophia Ran, Southern Illinois University School of Medicine, USA Dr. Homer S Black, Baylor College of Medicine, USA.

We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance towards the success of Cancer Science-2012. With the unique feedback from the conference.


Past Reports  Gallery  

Cancer Science-2011

The International Conference and Exhibition on Cancer Science and Therapy (Cancer Science-2011), hosted by the OMICS Group was held on August 15-17, 2011 in Las Vegas, USA. It attracted around 350 delegates from across the cancer science community of the world for a day of lively discussion and debate. The conference focused on the Novel approaches in cancer science & therapy.

We are particularly grateful to our conference chairs and Key note speakers: Dr. Mahin Khatami, National Cancer Institute, USA,Dr. Michael MIngzhao Xing, Johns Hopkins University School of Medicine, USA,Dr. Francois Vallete, INSERM and Universite de Nantes, France,Dr. Stephen Wang, Millennium Pharmaceuticals Inc, USA,Dr. Jimmy Efird, Brody School of Medicine, USA,Dr. John Thompson, University of Waterloo, Canada.

We are also grateful to other speakers and Senesco Technologies Inc., USA who supported the conference by facilitating the discussion forums. As part of a collaborative effort, Journal of Cancer Science & Therapy and Journal of Carcinogenesis & Mutagenesis has published all papers presented at this meeting as a special issue.Cancer science 2011 witnessed a success in great magnitude event.


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 17-18, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations